Pardanani et al reported the mutation-augmented prognostic scoring system (MAPSS) for a patient with systemic mastocytosis. This can help to identify a patient who may benefit from more aggressive management. The authors are from the Mayo Clinic.
Parameters:
(1) platelet count in 10^9/L
(2) age in years
(3) serum albumin in g/dL
(4) ASXL1 mutation
(5) hemoglobin in g/dL or transfusion dependence
Parameter
Finding
Points
platelet count
>= 150 * 10^9/L
0
< 150 * 10^9/L
2
age in years
<= 60 years
0
> 60 years
1.5
serum albumin
>= 3.5 g/dL
0
< 3.5 g/dL
1.5
ASXL1 mutation
no
0
yes
1.5
hemoglobin status
>= 10 g/dL and not transfusion dependent
0
< 10 g/dL
1
transfusion dependent
1
total score =
= SUM(points for all of the parameters)
Interpretation:
• minimum score: 0
• maximum score: 7.5
Total Score
Risk Group
Median Overall Survival
0 to 1.5
low
86 months
2 to 4.5
intermediate
21 months
5 to 7.5
high
5 months
To read more or access our algorithms and calculators, please log in or register.
